Organon is The Only Company of Its Size Focused Exclusively On Women’s Health

Organon South Africa aims to address the healthcare issues facing South African women and those in the sub-Saharan region, and in turn to significantly improve their health. With an international footprint that serves people in more than 140 markets, Organon’s mission is to deliver impactful medicines and solutions for healthcare issues facing women in sub-Saharan Africa.

Dr. Abofele Khoele joins Giselle Wertheim Aymes, Founder of World of Longevity, in this week’s Business of Health series, hosted on the Nielsen Network.

Organon’s Healthcare Solutions for Women in Sub-Saharan Africa

“Organon as a women’s health business is what makes it unique in the pharmaceutical space and we really have a focus in commitment for the health of women. No other large pharmaceutical company has the health of women as its primary focus, and our mission for a better and health every day for every woman is not only a commitment but also a call to action, to an area that for a long time has been neglected.

We want to listen to women and understand their health needs and also help identify appropriate, relevant solutions to those needs. We know women form 52% of the population in the country and across the African continent but sadly women’s access to education and health care has not been a priority”.

Organon will also focus on its important biosimilars business, focusing on oncology and inflammatory diseases, while maximising the value of its trusted dermatology, pain, respiratory and cardiovascular portfolio in countries around the world where there is still a great need for these treatments.

Photo by JESHOOTS.COM on Unsplash

“On the African continent, the need for health care, especially among women, is so broad. We know through the ages women have been the backbone of society in Africa. Often in the face of extreme adversity. But we also do know that there has been a disproportionate impact of the pandemic on the social and economic status of women in South Africa”.

Medicinal Portfolio

Organon’s portfolio consists of more than 60 medicines and products across an international footprint. The international footprint serves people in more than 140 markets.

Organon has core pillars that will benefit from renewed management focus and commercial investment. No other large global pharmaceutical company has the health of women as its primary therapeutic area of focus.

“Education is central to many things. I believe that education access and choice are all essential for a lot of women for equal opportunities in society. To fundamentally reduce poverty, inequality and advance the right for women and girls, we must guarantee equal access to health care services and ensure these services respond to the specific needs women have”.

Patient’s goals

Organon’s philosophy is to build a business around patient needs and identify and advance healthcare options for women to live their best lives every day.

Extensive resources will be poured into researching and developing new and innovative solutions to address women’s healthcare challenges.

The company’s extensive global capabilities in clinical development, patient safety, regulatory and medical affairs make it well-positioned to identify promising drugs, diagnostics, and devices with the greatest potential to impact women’s health.

Watch The Video

The video interview contains the full dialogue of this interview, and you can watch it below.